Cellular Origins Raises $40M Series A to Scale Cell Therapy Manufacturing Platform
核心洞察
Cambridge-based Cellular Origins (搜索) closed an oversubscribed $40 million Series A funding round led by Johnson & Johnson Innovation to advance its Constellation robotic automation platform for cell and gene therapy (搜索) manufacturing.
The company's technology addresses a critical bottleneck in the CGT sector, where current production systems serve fewer than 7% of eligible patients worldwide due to manufacturing limitations.
The funding will support commercial team expansion, platform development, and infrastructure scaling to enable production of hundreds of thousands of therapy doses while maintaining biological performance.
Cambridge-based Cellular Origins (搜索) has secured an oversubscribed $40 million Series A funding round to advance its robotic automation platform that addresses one of the most pressing challenges in cell and gene therapy (搜索) (CGT) manufacturing. The investment, led by Johnson & Johnson Innovation – JJDC, Inc., marks one of 2025's standout investments in advanced therapy manufacturing and comes as the sector grapples with production systems that currently serve fewer than 7% of eligible patients worldwide.
Addressing Critical Manufacturing Bottlenecks
The TTP Group (搜索) spin-out has developed the Constellation platform, a robotic automation system that connects existing third-party bioprocess instruments to create a scalable, space-efficient manufacturing workflow. The technology preserves biological performance while removing labor bottlenecks, offering pharmaceutical companies a viable route to commercial-scale therapy production.
"This fundraise is a pivotal milestone in our mission to industrialise cell therapy (搜索) manufacturing," said Edwin Stone, CEO of Cellular Origins (搜索). "It recognises the urgent need for scalable automation and gives us the resources to accelerate deployment of our platform so more patients can access life-saving therapies."
Strategic Investor Syndicate
The Series A round attracted participation from Highland Europe (搜索), BGF (搜索), NYBC Ventures (搜索), and TTP Group (搜索), bringing together combined expertise in life sciences, automated manufacturing, and global business scale-up. The syndicate's composition reflects the strategic importance of solving manufacturing challenges in the advanced therapeutics sector.
Luke Rajah, Partner at BGF (搜索), commented: "Cellular Origins (搜索) is tackling one of the most pressing challenges in advanced therapeutics – the ability to manufacture cell and gene therapies cost effectively at scale. The company's robotic automation platform integrates existing best-in-class manufacturing equipment from a range of top tier partners, and has the potential to transform access to life-changing treatments, globally."
Established Industry Partnerships
Cellular Origins (搜索) has already established partnerships with leading industry players including Cytiva (搜索), Fresenius Kabi, Thermo Fisher Scientific (搜索), and Wilson Wolf (搜索). These collaborations validate the platform's commercial potential and demonstrate industry recognition of the technology's ability to address manufacturing scalability challenges.
Expansion Plans and Future Development
The new funding will support expansion of the commercial team to meet increasing demand from pharmaceutical companies developing commercial and late-stage therapies. The investment will also accelerate integration of additional unit operations into the Constellation platform and development of infrastructure required for large-scale global manufacture.
The company plans to scale production capabilities to handle hundreds of thousands of therapy doses reliably and efficiently without compromising biological performance. Looking ahead, Cellular Origins (搜索) intends to extend its technology into the wider Advanced Therapies Medicinal Products (搜索) (ATMP) sector, where similar scaling challenges remain unmet.
The funding positions Cellular Origins (搜索) to address the fundamental manufacturing barriers that have limited patient access to potentially life-saving cell and gene therapies, with the goal of making these treatments more accessible, reliable, and affordable on a global scale.